Clinical Development (3)

Challenge A listed biotech company conducting Phase III clinical trials in an oncology indication needed Chief Medical Officer support for multiple clinical activities in Europe and the United States.

Challenge An oncology-focused biopharma company needed support to develop a pipeline of kinase inhibitors in early- and late-stage development.

Challenge: A venture capital-backed platform technology company wanted to develop its internal pipeline of therapeutic oncology candidates, while allowing prospective partners to access the...

Challenge An emerging drug discovery company, with a core expertise in molecular modelling, had developed a small molecule inhibitor for a novel cancer metabolism target. The company was looking to...

Oncology Scientific Advisory Board An emerging drug discovery company, with a core expertise in molecular modelling, had developed a small molecule inhibitor of a novel cancer metabolism target. The...

Challenge: Anti-nerve growth factor inhibitors are a new class of powerful analgesics in clinical development. They were put on clinical development hold by the FDA in 2012 due to joint-related...

Alacrita's consulting team supports a number of pharmaceutical & biotech companies with medical and clinical strategy. We have particular depth in oncology, but also have expertise in infectious...

A venture-backed biotech company, developing a clinical stage asset for the treatment of early stage cancer, was populating a dataroom and preparing for negotiations with a major pharmaceutical...

Alacrita Consulting's founders worked together for over 10 years at Onyvax, a London-based cancer immunotherapy company backed by SR One. We have conducted a number of consulting projects in the...

Challenge: A leading cancer research charity needed project management and drug development expertise to shepherd two preclinical programs into Phase I/II clinical trials. Alacrita was engaged to...